In what could be a major breakthrough for antibiotic research, Mumbai-based Wockhardt is all set to launch its novel antibiotic candidate WCK 5222, or Zaynich, in India by the end of 2024-25, followed by a global launch in 2025-26. The total addressable market for the antibiotic is estimated to be around $25 billion globally.
Wockhardt expects no competition for this drug worldwide for at least the next 15 years as there is no other similar drug in research pipelines. In India, around 750,000 patients are suffering from antimicrobial resistance (AMR), while in the US this number is around 500,000 and in the EU it is about 700,000. According to Wockhardt Chairman Habil Khorakiwala, the price of the antibiotic in India would be one-tenth of its global price.
Zaynich a combination of Zidebactam and Cefepime is effective in treating infections caused by drug-resistant pathogens. Basically, the drug is effective against all major superbugs that have become resistant to almost all antibiotics used today - often referred to as multi-drug resistant (MDR), or extensively drug resistant (XDR) pathogens.
Globally, mortality rate in patients infected with MDR superbugs is in excess of 30 per cent.
This story is from the June 29, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 29, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Air India cancels US flight to ferry T20 world champions
DGCA asks for 'factual report' from the airline
It's showtime for live entertainment
A heady cocktail of social media and youth craving for experiences has triggered a boom in live events. Can it last?
The fate of the compensation cess
In our piece yesterday, we reviewed the performance of the Goods and Services Tax (GST) over the past seven years, emphasising that the states did well but at the cost of a revenue sacrifice by the Centre.
Near-term headwinds seen for realty stocks
Analysts suggest cautious approach, advise against exiting completely
Strong outlook for AMCs but high valuations pose risk
Given gains in equity prices, it is not surprising that the earnings of asset management companies (AMCs) are growing quicker.
Sebi has strong case against Hindenburg, say lawyers
The Indian market regulator, the Securities and Exchange Board of India (Sebi), has a strong case against US-based short-seller Hindenburg Research, who the former has alleged to have traded based on unpublished price-sensitive information.
Sensex may hit 87K by year-end
Analysts advise investors to stay with largecaps
FMCG sector weight in Nifty 50 falls to lowest level since 2010
Weak financial results reason for waning investor interest: Analysts
Yin, yang and assumptions
India and China are two of the world's largest civilisations, countries and Leconomies.
Lagging indicator
Gender diversity in India Inc still sub-optimal
